[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100552496":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":31,"centralContacts":32,"locations":44,"responsibleParty":82,"collaborators":85,"id":89,"slug":90,"hasResults":91,"nctId":92,"briefTitle":93,"officialTitle":94,"acronym":31,"eligibilityCriteria":95,"healthyVolunteers":91,"sex":96,"minAge":97,"maxAge":31,"enrollmentInfo":98,"targetDuration":31,"studyType":101,"phases":102,"briefSummary":104,"conditions":105,"keywords":111,"overallStatus":64,"whyStopped":31,"lastUpdateSubmitDate":115,"lastUpdatePostDateStruct":116,"startDateStruct":119,"completionDateStruct":121,"leadSponsor":123,"locationsCount":124},{"fullName":5,"class":6},"Hospital Authority, Hong Kong","OTHER_GOV",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"SGLT2 inhibitor empagliflozin","EXPERIMENTAL","10mg daily from recruitment to hospital discharge",[13],"Drug: Empagliflozin 10 MG",{"label":15,"type":16,"description":17,"interventionNames":18},"Placebo","PLACEBO_COMPARATOR","1 tablet daily from recruitment to hospital discharge",[19],"Drug: Placebo",[21,28],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"DRUG","Empagliflozin 10 MG","Empagliflozin 10mg once daily from recruitment to hospital discharge",[9],[27],"Jardiance",{"type":22,"name":15,"description":29,"armGroupLabels":30,"otherNames":31},"Placebo single tablet once daily from recruitment to hospital discharge",[15],null,[33,39],{"name":34,"role":35,"phone":36,"phoneExt":37,"email":38},"Pauline Yeung Ng, MBBS, FHKCP","CONTACT","39103372","852","pyeungng@hku.hk",{"name":40,"role":35,"phone":41,"phoneExt":42,"email":43},"Calvin Tam, BSN, RN","07783323202","44","ct7331@hku.hk",[45,62,70],{"facility":46,"status":47,"city":48,"state":48,"zip":49,"country":48,"countryCode":50,"cosmosGeoPoint":51,"geoPoint":56,"contacts":57},"4\u002FF Main Clinical Block and Trauma Centre, Prince of Wales Hospital, Shatin, New Territories, Hong Kong","NOT_YET_RECRUITING","Hong Kong","0000","HK",{"type":52,"coordinates":53},"Point",[54,55],114.17469,22.27832,{"lat":55,"lon":54},[58],{"name":59,"role":35,"phone":60,"phoneExt":37,"email":61},"Lowell Ling, MBBS (UK), MPhil (Cantab)","3505 2735","lowell.ling@cuhk.edu.hk",{"facility":63,"status":64,"city":48,"state":48,"zip":49,"country":48,"countryCode":50,"cosmosGeoPoint":65,"geoPoint":67,"contacts":68},"Adult Intensive Care Unit, Queen Mary Hospital, 102 Pok Fu Lam Road, Hong Kong","RECRUITING",{"type":52,"coordinates":66},[54,55],{"lat":55,"lon":54},[69],{"name":34,"role":35,"phone":36,"phoneExt":37,"email":38},{"facility":71,"status":64,"city":48,"state":31,"zip":72,"country":48,"countryCode":50,"cosmosGeoPoint":73,"geoPoint":75,"contacts":76},"The University of Hong Kong","00",{"type":52,"coordinates":74},[54,55],{"lat":55,"lon":54},[77,80],{"name":78,"role":35,"phone":31,"phoneExt":31,"email":79},"Adrian Chan","adrianc2@hku.hk",{"name":34,"role":81,"phone":31,"phoneExt":31,"email":31},"PRINCIPAL_INVESTIGATOR",{"type":81,"investigatorFullName":83,"investigatorTitle":84,"investigatorAffiliation":5,"oldNameTitle":31,"oldOrganization":31},"Pauline Yeung Ng, MD","Clinical Assistant Professor",[86],{"name":87,"class":88},"Chinese University of Hong Kong","OTHER","100552496","efficacy-of-sglt2-inhibitors-in-adults-with-sepsis-100552496",false,"NCT06473844","Efficacy of SGLT2 Inhibitors in Adults With Sepsis","Efficacy and Safety of Sodium-Glucose Cotransporter 2 Inhibitors in Adults With Sepsis: A Feasibility Study for a Multicenter Double-Blind Randomized Placebo-Controlled Trial","Inclusion Criteria:\n\n* Aged 18 years or above\n* New onset of sepsis within 48 hours defined according to the Sepsis-3 criteria. (≥2 SOFA)\n* Provision of signed and dated informed consent form from participant or surrogate\n* Ability to take and adhere to oral and enteral medication regimen\n* Willingness to comply\n\nExclusion Criteria:\n\n* Current or recent use of SGLT2 inhibitors (within 12wks prior to randomization)\n* Impaired renal function\n* Clinically unstable or in refractory hypotension\n* History of ketoacidosis\n* Gastrointestinal surgery or GI absorption \u002F malabsorption disorder\n* Pregnancy\n* Known allergic or hypersensitivity reactions to any SGLT2 inhibitors\n* Treatment with another investigational drug or other interventions within 30 days prior to trial","ALL","18 Years",{"count":99,"type":100},60,"ESTIMATED","INTERVENTIONAL",[103],"NA","Goal of this clinical trial is to examine the safety and efficacy of SGLT2 inhibitors on the clinical outcomes in patients with sepsis. Main study outcomes are as follows:\n\n(i) Primary objective is to examine the efficacy and safety of SGLT2 inhibitors on clinical outcomes in patients with sepsis.\n\n(ii) Secondary objective is to examine the effect of SGLT2 inhibitors on inflammatory markers in patients with sepsis.",[106,107,108,109,110],"Sepsis","Inflammation","SGLT2 Inhibitors","Critically Ill","Organ Dysfunction Syndrome",[112,106,113,109,114],"SGLT2 inhibitors","Inflammatory Markers","Organ dysfunction","2025-03-17",{"date":117,"type":118},"2025-03-19","ACTUAL",{"date":120,"type":118},"2025-03-05",{"date":122,"type":100},"2027-02-28",{"name":5,"class":6},3]